Study-unit INNOVATIVE THERAPIES IN PHARMACOLOGY
| Course name | Industrial pharmacy |
|---|---|
| Study-unit Code | A003607 |
| Curriculum | Comune a tutti i curricula |
| Lecturer | Marco Gargaro |
| Lecturers |
|
| Hours |
|
| CFU | 4 |
| Course Regulation | Coorte 2023 |
| Supplied | 2023/24 |
| Supplied other course regulation | |
| Learning activities | Affine/integrativa |
| Area | Attività formative affini o integrative |
| Sector | BIO/14 |
| Type of study-unit | Opzionale (Optional) |
| Type of learning activities | Attività formativa monodisciplinare |
| Language of instruction | Italian |
| Contents | This course will provide students with a general overview of innovative immunology-based therapies currently under development for the treatment of rare diseases, oncological conditions, inflammatory disorders, and autoimmune diseases. In particular, the basic concepts of immunology necessary for understanding advanced next-generation cellular therapies will be provided. |
| Reference texts | Immunobiologia di Janeway, a cura di Kenneth Murphy, Casey Weaver, Massimo Locati, Piccin-Nuova Libraria, 2019. |
| Educational objectives | The main objective of this course is to provide students with the basic concepts for identifying and validating new immunological targets for the development of advanced and personalized pharmacological strategies. |
| Prerequisites | Successful completion of exams in General Pharmacology, Pharmacotherapy, and Experimental Pharmacology is required. Knowledge of these subjects is essential for students who wish to successfully pursue the course. |
| Teaching methods | Theoretical lessons |
| Other information | Recommended frequency |
| Learning verification modality | Oral exams |
| Extended program | This course will provide the basic concepts of immunology necessary for understanding advanced next-generation cellular therapies, including: - Innate and adaptive immunity; - Mechanisms of cellular communication; - Differentiation of immune cells; Furthermore, concepts for the development of cell-based biological drugs will be covered, such as: - Engineered immune cells for the treatment of solid or hematological tumors (CAR-T, CAR-NK, CAR-Mac); - Vaccines based on dendritic cells or viral vectors; - Engineered stem cells with viral vectors for the treatment of rare diseases; - Extracellular vesicles as carriers of biotherapeutics. |
| Obiettivi Agenda 2030 per lo sviluppo sostenibile | Health and wellness |